Cardio-Oncology Mediterranean group
Choose your language
Cardio-oncology
"Managing cardiovascular diseases in cancer patients"
Aims of the gmedico.fr web site
This site was created by Prof. Franck Thuny and Dr. Jennifer Cautela from the Mediterranean Center of Cardio-Oncology at the North University Hospital of Marseille, France (Aix-Marseille University).
-
to provide physicians with protocols for cardiovascular monitoring and management of patients treated for cancer established by cardiologists and oncologists with expertise in cardio-oncology based on international recommendations, the latest scientific knowledge and practical considerations.
-
to provide rapid access to potential cardiovascular toxicities by anti-cancer drugs used.
-
to provide information on education and research in cardio-oncology.
-
The website has been approved by The French Working Group on Cardio-Oncology.
-
We try to update our protocols as often as possible
-
Please note that although our protocols are based on international recommendations and published scientific data, they have not been validated by learned societies and cannot be used as a reference.
About cardio-oncology
Modern cancer treatments have dramatically improved the survival of cancer patients and have sometimes turned a fatal disease into a chronic illness.
Cardiovascular management of cancer patients is therefore a major challenge because cancer and cardiovascular disease often coexist, and cancer treatments can cause cardiac or vascular toxicity.
Thus, the risk of developing cardiovascular events can sometimes be greater than the risk of cancer recurrence and thus mitigate the overall long-term benefit expected.
It is therefore essential to specifically organize the cardiovascular follow-up of patients who need to receive a potentially toxic treatment for the cardiovascular system. It is in this context that cardio-oncology has emerged, whose main objective is to prevent, detect and manage cardiovascular diseases associated with or secondary to cancer treatment without compromising its efficacy. It therefore requires a good knowledge of cancer treatments and their toxicities, as well as close collaboration between cardiologists and oncologists.
Cardiovascular monitoring must be part of the patient care pathway from the time of diagnosis of cancer and should continue in the long term even after recovery.
